David A. Cory - Mar 11, 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc. (EIGR)

Role: President and CEO, Director
Signature: /s/ Sriram Ryali, Attorney-in-Fact
Stock symbol: EIGR
Transactions as of: Mar 11, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/11/2022, 08:06 PM
Previous filing: Jul 30, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EIGR	Common Stock	Award	$0	+47K	+38.47%	$0.00	169K	Mar 11, 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EIGR	Stock Option (Right to Buy)	Award	$0	+281K		$0.00	281K	Mar 11, 2022	Common Stock	281K	$5.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares underlying Restricted Stock Units award that will vest as to 33.3% on each of the first, second and third anniversaries of the grant date of March 11, 2022.
F2	The option vests in 48 equal monthly installments commencing on the grant date of March 11, 2022, subject to the Reporting Person's continuous service as of such date.
F3	Includes shares purchased under the Issuer's Employee Stock Purchase Plans as follows: 1,378 shares on September 5, 2020, 1,459 shares on September 3, 2021, and 1,500 shares on March 5, 2022.